BOSTON, March 13, 2025 (GLOBE NEWSWIRE) — Folia Health and Novartis Pharmaceuticals are teaming up for an exciting initiative aimed at helping those with IgA nephropathy (IgAN). This new study will allow participants to monitor their health from home, focusing on what matters most to them over a six-month observation period. By using Folia’s innovative technology, patients can track their symptoms and quality of life in a way that truly reflects their experiences, not just standard metrics.
This research is groundbreaking because it’s the first of its kind to gather real-world data on how people with IgAN manage their symptoms at home. Developed with input from IgAN patients, it aims to measure the real challenges they face and how different treatments affect their lives. As new treatments for IgAN emerge, these insights will be invaluable in understanding how they impact daily life.
With the Folia app, patients and their caregivers can actively participate by observing and tracking their health journeys. The app helps visualize trends in symptom severity, frequency of flare-ups, and how well treatments are working. Patients can export reports to share with their healthcare teams, making consultations more informed and effective. Since the study is entirely remote, participants can take part without needing to visit a clinic, further enhancing convenience.
Nell Meosky Luo, CEO of Folia Health, stated, “We aim to empower individuals with chronic conditions to manage their care effectively. This IgAN program is a step towards understanding treatment effectiveness and the realities of living with this condition.” Briana Ndife, Director of HEOR, Nephrology at Novartis, emphasized the importance of collecting detailed, home-reported data saying, “This program captures the nuanced experiences of patients over time, providing a clearer picture of disease progression and treatment impact.”
Access to real-time insights can also change how patients approach their treatments. A recent survey indicated that 85% of patients feel more empowered when they can track their health data actively, and this initiative caters to that need. The project aligns with a growing trend of personalized healthcare, where patient involvement is key.
Folia Health is at the forefront of redefining how patient experiences contribute to better healthcare solutions. By collecting and analyzing data from daily life, they are proving that what happens outside the clinic can provide just as critical information as traditional medical assessments. For further insights into the potential of home-reported outcomes, you can visit Folia Health.
Novartis Pharmaceuticals is known for its commitment to rethinking medicine for better health outcomes worldwide, reaching over 250 million patients. Their collaboration with Folia highlights the importance of patient-centered research in the ongoing battle against chronic diseases.
Check out this related article: Empowering Voices: Asha Health Workers in India Demand Fair Wages and Recognition
Source linkFolia Health, clinicaltrials, digital health, drug development, real world evidence, real world data, IgA nepropathy, IgAN, observational research
